Kiromic BioPharma, Inc. Overview
Pro stress-test →Kiromic BioPharma is an AI-driven, end-to-end allogeneic cell therapy company currently developing multi-indication allogeneic T cell therapy that exploits the natural potency of Gamma Delta T cells (GDT) to target solid tumors. The company uses its proprietary DIAMOND® artificial intelligence (AI) 2.0 platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology.
Strategic Profile
Pro stress-test →With proprietary DIAMOND AI technology streamlining target discovery, Kiromic is positioned to rapidly expand its pipeline in innovative drug discovery and precision medicine markets. The company advanced its lead program Deltacel™ (KB-GDT-01), an allogeneic, off-the-shelf Gamma Delta T-cell therapy, with a Phase 1 clinical trial for stage 4 metastatic or locally-advanced non-small cell lung cancer as of January 2025.
Competitive Landscape
Pro stress-test →Kiromic competes in the allogeneic cell therapy space against CAR-T focused players and other immuno-oncology developers. Its GDT platform differs from the more widely explored CAR-T approaches, positioning it as a differentiated but earlier-stage player. Competitors include both public and private cell therapy developers pursuing universal off-the-shelf therapies.
Industry Context
Kiromic BioPharma, Inc. operates in Allogeneic cell therapy development.
Key facts
Founded: 2016 · Headquarters: Houston, US · Employees: 18 (as of May 2026) · Revenue: N/A · Market cap: $265M (as of March 13, 2026)